PMID- 22729223 OWN - NLM STAT- MEDLINE DCOM- 20121009 LR - 20231120 IS - 1546-1718 (Electronic) IS - 1061-4036 (Print) IS - 1061-4036 (Linking) VI - 44 IP - 8 DP - 2012 Jun 24 TI - De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. PG - 941-5 LID - 10.1038/ng.2329 [doi] AB - De novo somatic mutations in focal areas are well documented in diseases such as neoplasia but are rarely reported in malformation of the developing brain. Hemimegalencephaly (HME) is characterized by overgrowth of either one of the two cerebral hemispheres. The molecular etiology of HME remains a mystery. The intractable epilepsy that is associated with HME can be relieved by the surgical treatment hemispherectomy, allowing sampling of diseased tissue. Exome sequencing and mass spectrometry analysis in paired brain-blood samples from individuals with HME (n = 20 cases) identified de novo somatic mutations in 30% of affected individuals in the PIK3CA, AKT3 and MTOR genes. A recurrent PIK3CA c.1633G>A mutation was found in four separate cases. Identified mutations were present in 8-40% of sequenced alleles in various brain regions and were associated with increased neuronal S6 protein phosphorylation in the brains of affected individuals, indicating aberrant activation of mammalian target of rapamycin (mTOR) signaling. Thus HME is probably a genetically mosaic disease caused by gain of function in phosphatidylinositol 3-kinase (PI3K)-AKT3-mTOR signaling. FAU - Lee, Jeong Ho AU - Lee JH AD - Institute for Genomic Medicine, Rady Children's Hospital, University of California, San Diego, La Jolla, California, USA. FAU - Huynh, My AU - Huynh M FAU - Silhavy, Jennifer L AU - Silhavy JL FAU - Kim, Sangwoo AU - Kim S FAU - Dixon-Salazar, Tracy AU - Dixon-Salazar T FAU - Heiberg, Andrew AU - Heiberg A FAU - Scott, Eric AU - Scott E FAU - Bafna, Vineet AU - Bafna V FAU - Hill, Kiley J AU - Hill KJ FAU - Collazo, Adrienne AU - Collazo A FAU - Funari, Vincent AU - Funari V FAU - Russ, Carsten AU - Russ C FAU - Gabriel, Stacey B AU - Gabriel SB FAU - Mathern, Gary W AU - Mathern GW FAU - Gleeson, Joseph G AU - Gleeson JG LA - eng GR - P30 NS047101/NS/NINDS NIH HHS/United States GR - HHMI/Howard Hughes Medical Institute/United States GR - R01 NS048453/NS/NINDS NIH HHS/United States GR - R01 NS038992/NS/NINDS NIH HHS/United States GR - R01 NS083823/NS/NINDS NIH HHS/United States GR - U54 HG003067/HG/NHGRI NIH HHS/United States GR - P30NS047101/NS/NINDS NIH HHS/United States GR - U54HG003067/HG/NHGRI NIH HHS/United States GR - R01 NS041537/NS/NINDS NIH HHS/United States GR - R01 NS052455/NS/NINDS NIH HHS/United States GR - P01 HD070494/HD/NICHD NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20120624 PL - United States TA - Nat Genet JT - Nature genetics JID - 9216904 RN - EC 2.7.1.1 (MTOR protein, human) RN - EC 2.7.1.137 (Class I Phosphatidylinositol 3-Kinases) RN - EC 2.7.1.137 (PIK3CA protein, human) RN - EC 2.7.11.1 (AKT3 protein, human) RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) RN - EC 2.7.11.1 (TOR Serine-Threonine Kinases) SB - IM MH - Child, Preschool MH - Class I Phosphatidylinositol 3-Kinases MH - DNA Mutational Analysis MH - Exome MH - Female MH - Humans MH - Infant MH - Magnetic Resonance Imaging MH - Male MH - Malformations of Cortical Development/*genetics/metabolism/pathology MH - Mosaicism MH - *Mutation, Missense MH - Phosphatidylinositol 3-Kinases/*genetics MH - Proto-Oncogene Proteins c-akt/*genetics MH - Signal Transduction/genetics MH - TOR Serine-Threonine Kinases/*genetics PMC - PMC4417942 MID - NIHMS683085 EDAT- 2012/06/26 06:00 MHDA- 2012/10/10 06:00 PMCR- 2015/05/04 CRDT- 2012/06/26 06:00 PHST- 2012/03/30 00:00 [received] PHST- 2012/05/24 00:00 [accepted] PHST- 2012/06/26 06:00 [entrez] PHST- 2012/06/26 06:00 [pubmed] PHST- 2012/10/10 06:00 [medline] PHST- 2015/05/04 00:00 [pmc-release] AID - ng.2329 [pii] AID - 10.1038/ng.2329 [doi] PST - epublish SO - Nat Genet. 2012 Jun 24;44(8):941-5. doi: 10.1038/ng.2329.